RT Journal Article
SR Electronic
T1 Ultra-Rapid Droplet Digital PCR Enables Intraoperative Tumor Quantification
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.29.24308126
DO 10.1101/2024.05.29.24308126
A1 Murphy, Zachary R.
A1 Bianchini, Emilia C.
A1 Smith, Andrew
A1 Körner, Lisa I.
A1 Russell, Teresa
A1 Reinecke, David
A1 Wang, Yuxiu
A1 Snuderl, Matija
A1 Orringer, Daniel A.
A1 Evrony, Gilad D.
YR 2024
UL http://medrxiv.org/content/early/2024/05/31/2024.05.29.24308126.abstract
AB The diagnosis and treatment of tumors often depends on molecular-genetic data. However, rapid and iterative access to molecular data is not currently feasible during surgery, complicating intraoperative diagnosis and precluding measurement of tumor cell burdens at surgical margins to guide resections. To address this gap, we developed Ultra-Rapid droplet digital PCR (UR-ddPCR), which can be completed in 15 minutes from tissue to result with an accuracy comparable to standard ddPCR. We demonstrate UR-ddPCR assays for the IDH1 R132H and BRAF V600E clonal mutations that are present in many low-grade gliomas and melanomas, respectively. We illustrate the clinical feasibility of UR-ddPCR by performing it intraoperatively for 13 glioma cases. We further combine UR-ddPCR measurements with UR-stimulated Raman histology intraoperatively to estimate tumor cell densities in addition to tumor cell percentages. We anticipate that UR-ddPCR, along with future refinements in assay instrumentation, will enable novel point-of-care diagnostics and the development of molecularly-guided surgeries that improve clinical outcomes.Competing Interest StatementNew York University Grossman School of Medicine has filed a provisional patent on the technology, listing Z.R.M., D.A.O., and G.D.E. as inventors. D.A.O. is a medical advisor and shareholder of Invenio Imaging, Inc., a company developing and marketing stimulated Raman histology microscopes. D.A.O. is also a consultant to Servier, a company whose portfolio includes IDH inhibitors. M.S. is a scientific advisor and shareholder of Heidelberg Epignostix and Halo Dx, is a scientific advisor of Arima Genomics and InnoSIGN, and has received research funding from Lilly USA. Other authors declare no competing interests.Funding StatementThis work was supported by discretionary laboratory start-up funds (G.D.E.) and by National Institutes of Health grant R01-CA226527 (D.A.O.). A QX200 system, reagents, and consumables were provided by Bio-Rad for the intraoperative phase of the project. Bio-Rad provided these items in-kind, without any input into the scientific conduct, analysis, or publication of this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of New York University Grossman School of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.